Literature DB >> 12829914

Cross-species costimulation: relative contributions of CD80, CD86, and CD40.

Nicola J Rogers1, Ian M Jackson, William J Jordan, Muhamed A Hawadle, Anthony Dorling, Robert I Lechler.   

Abstract

BACKGROUND: The response of human CD4+ T cells against porcine cells is of comparable magnitude to that induced by human leukocyte antigen-mismatched allogeneic cells. This reflects productive interactions between key costimulatory molecules across the species barrier. Inhibition of these molecular interactions will be crucial in overcoming CD4+ T-cell-mediated rejection of xenografts. We have performed a detailed investigation to determine the expression profiles and relative contributions of the three key costimulatory molecules in the porcine-human xenogeneic response. Whereas only porcine CD86 is constitutively expressed on resting endothelial cells, both CD40 and CD80 are rapidly expressed after activation. All three costimulatory molecules are expressed by professional antigen-presenting cells.
METHODS: We have isolated full-length cDNA clones for human and porcine CD80, CD86, and CD40. Human fibroblast cell lines (M1) coexpressing DR1 were transfected with these cDNAs and used in mixed lymphocyte reactions and flow cytometric studies in vitro.
RESULTS: These data provide the first characterization of the expression profile and functional role of porcine CD80. Functional assays demonstrate that pCD40, pCD80, and pCD86 are independently capable of costimulating human CD4+ T cells, albeit with differing kinetics. Proliferative responses were of comparable magnitude to those obtained when costimulation was provided by human CD40, CD80, and CD86.
CONCLUSIONS: These data have implications for therapy targeting the direct pathway of xenorecognition; costimulatory molecule blockade must be directed against both the B7/CD28 and CD40/CD40L pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829914     DOI: 10.1097/01.TP.0000069100.67646.08

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

Review 2.  Antibody-mediated xenograft injury: mechanisms and protective strategies.

Authors:  Richard N Pierson
Journal:  Transpl Immunol       Date:  2009-04-17       Impact factor: 1.708

Review 3.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

4.  Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells.

Authors:  Corin Ezzelarab; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2012-09-13       Impact factor: 3.907

5.  Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules.

Authors:  Tadatsura Koshika; Carol Phelps; Jason Fang; Seung Eun Lee; Minoru Fujita; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 6.  New concepts of immune modulation in xenotransplantation.

Authors:  Vikas Satyananda; Hidetaka Hara; Mohamed B Ezzelarab; Carol Phelps; David Ayares; David K C Cooper
Journal:  Transplantation       Date:  2013-12-15       Impact factor: 4.939

7.  Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs.

Authors:  Hidetaka Hara; Naoko Koike; Cassandra Long; Jordan Piluek; Danny S Roh; Nirmala SundarRaj; James L Funderburgh; Yoshiaki Mizuguchi; Kumiko Isse; Carol J Phelps; Suyapa F Ball; David L Ayares; David K C Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-15       Impact factor: 4.799

8.  Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Authors:  Lazar Vujanovic; Theresa L Whiteside; Douglas M Potter; Jessica Chu; Soldano Ferrone; Lisa H Butterfield
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

9.  Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status.

Authors:  Hidetaka Hara; William Witt; Tanner Crossley; Cassandra Long; Kumiko Isse; Liming Fan; Carol J Phelps; David Ayares; David K C Cooper; Yifan Dai; Thomas E Starzl
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 10.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.